GlassScriptPhysician profile
Bhupinder Kaur
NPI 1457779993
$384.35
in general payments reported to CMS, 2019-2025
11 companies · $88.24 in 2025
The $88.24 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2023: $87.63 · 2024: $71.54 · 2025: $88.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $247.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $46.11 | 2023-2025 | Rexulti |
| Alkermes, INC. | $41.46 | 2025 | Aristada, Lybalvi |
| Lundbeck LLC | $33.96 | 2024 | Abilify Asimtufii, Rexulti |
| Exact Sciences Corporation | $33.52 | 2023-2024 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $20.95 | 2023 | Auvelity |
| Qiagen, LLC | $20.39 | 2024 | |
| Pulmonx Corporation | $19.45 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Teva Pharmaceuticals USA, INC. | $18.30 | 2025 | Austedo Xr |
| Daiichi Sankyo INC. | $16.78 | 2021 | |
| Glaxosmithkline, LLC. | $13.27 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhupinder Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.